Safety, Tolerability and Feasibility of Treatment with GP120-activated Regulatory T cells (ATreg) Early After Haematopoietic Stem Cell Transplantation (HSCT) to Reduce the Incidence and Severity of Acute Graft vs Host Disease (GvHD)

This study is open to adults aged 18 and over, of any sex. You would typically be someone who has been diagnosed with leukaemia and is scheduled to have, or has recently had, a stem cell transplant.

There will be specific health requirements and other medical checks to make sure the study is a good fit for you and that taking part is safe. For example, your general health, other medical conditions, and any medications you are taking will all be carefully considered.

The research team will discuss all the details with you to confirm if you meet the specific criteria for joining the study. This is to ensure the treatment is suitable for your individual health situation.

If you join this study, you would receive the ATreg treatment soon after your stem cell transplant. Researchers will then closely monitor your health for a period of time. This will involve several visits to the hospital for checks, which may include blood tests to look at your aGVHD symptoms, and to see how your body is responding to the treatment and the transplant. You will also be monitored for any side effects. These assessments will be more frequent in the first few weeks (e.g., within 24 hours, 3 days, 7 days, and 14 days after receiving ATreg), and then continue periodically for up to 6 months to track your progress, particularly concerning GvHD, infections, and how well your new blood cells are developing. The exact total duration of your participation, including follow-up, will be detailed by the study team.